Thrombin generation in the Glasgow myocardial infarction study by Smid, Machiel et al.
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
 
 
 
 
Smid, M., Dielis, A. W. J. H., Spronk, H. M. H. S., Rumley, A., van 
Oerle, R., Woodward, M., ten Cate, H., and Lowe, G. (2013) Thrombin 
generation in the Glasgow myocardial infarction study. PLoS ONE, 8(6), 
e66977. 
 
 
 
Copyright © 2013 The Authors 
 
 
This work is made available under the Creative Commons 4.0  License 
(CC BY4.0)      
 
 
 
 
Version: Published 
 
 
http://eprints.gla.ac.uk/84996/  
 
 
 
 
 
Deposited on: 29 May 2015 
 
 
Thrombin Generation in the Glasgow Myocardial
Infarction Study
Machiel Smid1, Arne W. J. H. Dielis1, Henri M. H. Spronk1, Ann Rumley2, Rene van Oerle1,
Mark Woodward3, Hugo ten Cate1*, Gordon Lowe2
1 Laboratory of Clinical Thrombosis and Haemostasis, Department of Internal Medicine, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The
Netherlands, 2 Institute of Cardiovascular and Medical Studies, University of Glasgow, Glasgow, United Kingdom, 3George Institute, University of Sydney, Sydney,
Australia
Abstract
Background: Thrombin is a key protease in coagulation also implicated in complex pathology including atherosclerosis. To
address the role of thrombin in relation to myocardial infarction (MI) we explored thrombin generation analysis in plasma
from patients and controls that had participated in the Glasgow MI Study (GLAMIS).
Methods: Thrombin generation at 1 and 2 pM TF and with and without thrombomodulin (TM) was performed on plasmas
from 356 subjects (171 cases, 185 age and sex matched controls) from GLAMIS collected between 3 and 9 months after the
MI event.
Results: Although thrombin generation was slightly delayed in cases (lag time increased from 3.3 to 3.6 min) at the highest
trigger, the overall potential to generate thrombin was increased by 7% for the ETP and by 15% for the peak height (both at
the 1 pM TF trigger) in cases. Addition of TM did not reveal differences. Furthermore, an increased thrombin generation was
associated with MI [normalized ETP: adjusted OR for the highest percentile = 2.4 (95% CI 1.3–4.5) and normalized peak
height: adjusted OR= 2.6 (1.3–5.0)] at the lowest trigger; normalized ETP and peak height being 2.1 (1.1–3.8) and 2.0 (1.0–
4.1) at the higher 2 pM trigger.
Conclusion: In GLAMIS, patients with a previous MI had an increased thrombin generation compared to controls. The
absence of a clear difference in TM reduction suggests an unaltered anticoagulant activity in these patients. Further
research is needed in order to unravel the underlying mechanisms of enhanced thrombin generation after MI.
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Introduction
In the pathogenesis of acute myocardial infarction (MI)
common risk factors for atherosclerosis as well as hemostatic
factors are important determinants. Thrombin is a central enzyme
in the blood coagulation cascade, regulating platelet activity and
fibrin clot formation. In addition, thrombin appears to modulate
atherosclerosis formation and plaque phenotype, at least in
experimental studies [1]. Clinically, markers of thrombin gener-
ation have been linked to risk of recurrent arterial thrombosis, but
the evidence is still weak [2]. We recently showed that the level of
thrombin generation in plasma was elevated during and following
a first MI [3]. Contra-intuitively, endogenous thrombin potential
(ETP), one of the main parameters derived from thrombin
generation analysis, tended to be lower in those who had a
subsequent recurrent arterial vascular event, which in conjunction
with an elevated level of D-dimer yielded a significant risk for
recurrence of 5.8 [3]. These analyses were however confined to
plasma samples collected during the acute phase of AMI. Since
in vitro thrombin generation analysis is typically aimed at
establishing the potential to generate thrombin in a given plasma
aliquot, rather than the actual amount of thrombin formed in vivo
in the acute phase, we set out to compare thrombin generation in
plasma samples collected in individuals with previous myocardial
infarction and matched controls, collected in the Glasgow
Myocardial Infarction Study (GLAMIS). Since, in patients with
stable coronary artery disease we expected only modest differences
in clotting potential we chose to stimulate plasma with low levels of
tissue factor, ie the commonly used 1 pM as well as a slightly
higher 2 pM tissue factor concentration. We calculated odds ratios
for myocardial infarction based on in vitro thrombin generation
data, in order to assess the importance of thrombin formation in
plasma, in the absence of platelets, as a risk factor for coronary
artery disease.
Methods
As described in previous papers [4,5] GLAMIS was established
to investigate associations of plasma haemostatic and inflamma-
tory variables with previous myocardial infarction (MI) and
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conventional risk factors in a case-control study. The aim was to
recruit all men and women with MI in the North Glasgow
MONICA study [6] diagnosed by W.H.O. - MONICA criteria
from July 1994, between 3 and 9 months after the event,
minimizing acute phase influences. Cases were patients with MI in
this population survey who were still alive and willing to give
consent (75% response rate). Controls were selected from a
random sample of the same north Glasgow population, obtained
from general practice registers, and frequency matched for sex and
age (within 1 year), who had no history or electrocardiogram
evidence of MI. Written informed consent was obtained from all
participants, and the study was approved by the local Research
Ethics Committee: Greater Glasgow Health Board Research
Ethics Committee. Participants completed a general health
questionnaire and blood pressure was recorded. A forearm venous
sample was taken after a full overnight fast and care was taken to
have properly collected blood samples in all individuals. Lipid
assays were measured as previously described [4]. Venous blood
was anticoagulated with trisodium citrate (3.2%(w/v)) and
centrifuged at 20006g for 10 min at room temperature within
2 h of sampling, and aliquots were stored at 270uC until assay.
For these analyses only previously unthawed plasma samples were
used.
Thrombin Generation Assay
One of the methods developed for studying in vitro thrombin
generation in plasma is the Calibrated Automated Thrombogram
(CAT: Thrombinoscope BV, Maastricht, The Netherlands). This
assay is based on the principle that rather than assessing the
coagulation status at a single timepoint, the potential to clotting
could reveal the actual risk of clotting under pathologic conditions,
eg plaque rupture. To this end plasma is usually triggered with
small amounts of tissue factor (TF) and the thrombin generation
curve is measured in time. By adding thrombomodulin also the
influence of the natural anticoagulant protein C system can be
addressed. Briefly, in vitro thrombin generation in platelet-poor
plasma was measured by means of the CAT method (Thrombino-
scope BV, Maastricht, the Netherlands), which employs a low
affinity fluorogenic substrate for thrombin to continuously monitor
thrombin activity in plasma. Measurements were conducted in
80 mL platelet-poor plasma in a total volume of 120 mL (20 mL
fluorogenic substrate, calcium and 20 mL solution of TF and
phospholipids). Final concentrations of TF were 1 (PPP Reagent
Low) and 2 pM TF (kind gift of Thrombinoscope BV) in the
presence of 4 mM phospholipids (phosphatidylserine/phosphati-
dylcholine/phosphatidylethanolamine vesicles in HEPES-buffered
saline). Since we anticipated that differences in the thrombin
generating potential would be modest between cases and controls
under non-acute conditions, we chose two low stimuli of plasma: 1
and 2 pM of TF [3]. Although this would theoretically pose a risk
of being susceptible to contact activation, based on our previous
data we did not expect much contact activity influence at TF
concentrations .1 pM [7]. In order to have a trigger that would
be a little more robust we also tested a 2 pM TF concentration.
To assess the contribution of the protein C pathway on in vitro
thrombin generation, all measurements were conducted in the
absence and presence of thrombomodulin (TM), titrated to obtain
50% reduction in ETP of normal pooled platelet poor plasma [8].
In order to correct for inner-filter effects and substrate consump-
tion, each thrombin generation measurement was calibrated
against the fluorescence curve obtained in the same plasma to
which a fixed amount of thrombin-a2-macroglobulin complex was
added (Thrombin Calibrator, Thrombinoscope BV). Fluorescence
was read in a Fluoroskan Ascent reader (Thermo Labsystems OY,
Helsinki, Finland) equipped with a 390/460 nm filter set and
thrombin generation curves were calculated with Thrombinoscope
software (Thrombinoscope BV). Three parameters were derived
from the thrombin generation curves: lag time (initiation phase of
coagulation), endogenous thrombin potential (ETP; area under the
thrombin generation curve), and peak height. Within and between
run coefficients of variations for in vitro thrombin generation were
below 10% for all parameters derives, as described previously [9].
Statistical Analysis
Thrombin generation data for lag time, normalized ETP
(nETP), normalized peak height (nPeak Height) and reduced
ETP were not normally distributed and are thus presented as
median [95% CI]. Differences between cases and controls were
calculated using the Mann-Whitney U test.
Thrombin generation parameters were categorized based on
the cut-off values of the highest 10% in the control group. Logistic
regression was used to obtain odds ratios (ORs) and corresponding
95% confidence intervals (95% CI) as a measure of relative risk
with the lowest category as a reference category. Analyses were
adjusted for the stratification factors: hypertension (defined as
diastolic blood pressure .90 mmHg and/or systolic blood
pressure .140 mmHg), BMI, hyperlipidemia (defined as total
cholesterol .6 mmol/L), diabetes mellitus, (history of) smoking,
and gender. All statistical analyses were performed using SPSS
version 19. P,0.05 was considered statistically significant.
Results
The present analysis includes 171 cases and 185 controls.
Baseline characteristics are indicated in Table 1, showing
significantly more unfavorable risk factors and biochemical
parameters in the cases compared to the controls, except for both
systolic and diastolic blood pressure, which were higher in the
control group. With regard to medication, we excluded any users
of oral anticoagulants, because of its known inhibitory effect on
thrombin generation. Aspirin and statins were used in 95% and
18% of cases and in 12 and 2% of controls, respectively.
Thrombin Generation
Table 2 and Figure 1 show thrombin generation parameters for
cases and controls. The ETP and peak height were normalized
against pooled plasma from healthy donors in order to correct for
between run variance, as reported previously [9]. Although not
significant, thrombin generation triggered with 1 pM TF was
delayed in cases as indicated by a prolongation of the lag time
from 5.6 min for controls to almost 6.0 min (p.0.05) for cases,
whereas the overall potential to generate thrombin was signifi-
cantly increased in cases. Both the normalized ETP (180% [145–
206]) and peak height (245% [170–324]) were enhanced in cases
compared to controls (ETP: 168% [143–189], peak height: 213%
[166–279], p,0.05). Prolongation of the lag time (3.61 min [3.00–
4.00] vs. 3.33 min [2.94–3.67], p,0.05) for cases was confirmed
by thrombin generation triggered with 2 pM TF. At this higher
TF trigger, the normalized ETP and peak height were both higher
in cases than in controls but the difference was not statistically
significant. At both TF triggers, the addition of thrombomodulin
did not reveal any differences in reduction of the ETP between
cases and controls (Table 2).
Thrombin generation parameters showed statistically significant
correlations with some of the classical risk factors for myocardial
infarction, including BMI, cholesterol and triglycerides (Table 3).
However, almost all correlations were weak (Rs,0.35) and not
always consistent between the 1 and 2 pM TF trigger (HDL). All
Thrombin Generation and Myocardial Infarction
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risk factors (age, BMI, hypercholesterolemia, hypertension, diabe-
tes and gender) were included in the multivariate analysis.
Table 4 shows the odds ratios (ORs) for myocardial infarction
for the different thrombin generation parameters, triggered with
both 1 and 2 pM tissue factor. Unadjusted ORs for myocardial
infarction with increasing thrombin generation parameters at
1 pM of TF trigger were 2.7 (95% CI 1.4–4.9) for the normalized
ETP and 2.5 (95% CI 1.3–4.6) for the normalized peak height for
cases in the highest 10th percentile. ORs for the lag time and ETP
reduction in the presence of TM were not statistically significant
(Table 4). Analysis of thrombin generation parameters obtained
with the 2 pM tissue factor trigger revealed essentially similar ORs
as those for 1 pM TF (Table 4).
Adjustment for putative confounders (age, gender, BMI,
hypertension, smoking, diabetes, hypercholesterolemia) attenuated
the OR for the normalized ETP to 2.4 (95% CI 1.3–4.5) and
enhanced the OR for the normalized peak height to 2.6 (95% CI
1.3–5.0), both assessed with the 1 pM TF trigger. At 2 pM TF,
adjusted ORs for myocardial infarction for the normalized ETP
and peak height were comparable to the 1 pM condition showing
increased OR’s for normalized peak and ETP in cases versus
controls (Table 4). The use of aspirin or statins did not significantly
affect any of the thrombin generation variables (data not shown).
Discussion
The present data show that in patients with previous myocardial
infarction in vitro thrombin generation in plasma is altered as
compared to control individuals, showing a prolonged lag time (at
Table 1. Baseline characteristics.
Cases Controls p
(n=171) (n =185)
Age (years) 54.4 (7.7) 54.2 (7.7) 0.86
Gender (male,
n(%))
126 (73.7) 137 (74.1) 0.94
Risk factors
Smoking (n, (%))
Ex and
current
153 (89.5) 136 (73.5)
Never 16 (9.4) 49 (26.5) ,0.01
Diabetes (n, (%)) 18 (10.5) 3 (1.6) ,0.01
Blood pressure
Systolic (mmHg) 124.6 (22.0) 129.6 (21.0) 0.06
Diastolic (mmHg) 79.4 (13.8) 81.9 (11.3) 0.03
BMI (kg/m2) (kg/m2) 28.0 (5.0) 26.6 (4.3) ,0.01
Lipid profile
Total
Cholesterol
(mmol/L) 6.0 (1.2) 5.8 (1.0) 0.03
HDL (mmol/L) 1.1 (0.3) 1.4 (0.4) ,0.01
Triglycerides (mmol/L) 2.2 (1.5) 1.8 (1.5) ,0.01
Data are presented as mean (standard deviation).
doi:10.1371/journal.pone.0066977.t001
Figure 1. Thrombin generation triggered with either 1 or 2 pM tissue factor (TF) in cases and controls.
doi:10.1371/journal.pone.0066977.g001
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the 2 pM tissue factor trigger only) and an increased normalized
ETP and peak height (albeit at the 1 pM TF concentration only).
Moreover, those cases with the highest levels of thrombin
generation (normalized ETP and peak height values) also have
an increased risk of MI, with adjusted OR’s of between 2 and 2.6,
for the different test conditions. Taken together, these data suggest
that the sustained increased thrombin generation potential is a
pathophysiologically relevant characteristic and indicator of a
hypercoagulable state in plasma from patients with coronary
disease. The prolonged lag time in cases of the present study is in
accordance with the observation in the MARK study, where
lagtime was prolonged in the acute phase but also at later
timepoints [3]. This prolongation may be due to release of TFPI
from perturbed endothelium such as demonstrated in a recent case
control study in young women with manifestations of arterial
thrombosis (AMI or stroke) [10]. However, also other changes in
the balance between pro- and anticoagulant proteins may be
involved in the alterations in thrombin generation profile.
Table 3. Correlation coefficients (Rs) between common risk factors for myocardial infarction and thrombin generation parameters.
Lag Time nETP nPeak Height reduced ETP
r p r p r p r p
@ 1 pM TF
Age 20.053 (0.318) 0.043 (0.419) 0.033 (0.537) 0.139 (0.009)
Blood pressure
Systolic 0.012 (0.818) 0.096 (0.070) 0.055 (0.303) 0.014 (0.791)
Diastolic 0.082 (0.123) 0.093 (0.080) 0.040 (0.455) 20.072 (0.178)
BMI 0.140 (0.009) 0.265 (0.000) 0.216 (0.000) 0.083 (0.120)
Lipid profile
Total Cholesterol 0.227 (0.000) 0.134 (0.011) 0.056 (0.298) 20.083 (0.119)
HDL 20.240 (0.000) 20.114 (0.032) 20.071 (0.186) 20.038 (0.477)
Triglycerides 0.273 (0.000) 0.210 (0.000) 0.211 (0.000) 0.084 (0.116)
@ 2 pM TF
Age 20.010 (0.848) 0.037 (0.486) 0.062 (0.240) 0.170 (0.002)
Blood pressure
Systolic 0.059 (0.267) 0.044 (0.405) 20.004 (0.945) 0.004 (0.941)
Diastolic 0.064 (0.227) 0.062 (0.243) 20.033 (0.532) 20.083 (0.127)
BMI 0.181 (0.001) 0.283 (0.000) 0.185 (0.000) 0.027 (0.614)
Lipid profile
Total Cholesterol 20.248 (0.000) 0.110 (0.032) 20.016 (0.436) 20.200 (0.000)
HDL 0.248 (0.000) 0.114 (0.039) 20.042 (0.758) 0.020 (0.710)
Triglycerides 0.323 (0.000) 0.117 (0.001) 0.084 (0.114) 20.086 (0.113)
nETP: normalized endogenous thrombin generation, nPeak Height: normalized peak height. Data are presented as R (p-value).
doi:10.1371/journal.pone.0066977.t003
Table 2. Thrombin generation.
Cases Controls p
@ 1 pM TF (n = 171) (n = 185)
Lag Time (min) 5.94 (5.00–6.67) 5.61 (4.67–6.67) n.s.
nETP (%) 180 (145–206) 168 (143–189) 0.023
nPeak Height (%) 245 (170–324) 213 (166–279) 0.017
reduced ETP (%) 233 (220– 243) 236 (222– 246) n.s.
@ 2 pM TF
Lag Time (min) 3.61 (3.00–4.00) 3.33 (2.94–3.67) 0.025
nETP (%) 213 (184–239) 204 (184–227) n.s.
nPeak Height (%) 236 (183–290) 221 (177–267) n.s.
reduced ETP (%) 241 (227– 253) 243 (232– 256) n.s.
Data are presented as median [IQR] for lag time, normalized ETP (nETP), normalized peak height (nPeak Height) and the reduction on ETP upon addition of
thrombomodulin (reduced ETP). Thrombin generation was assessed at a trigger of 1 or 2 pM tissue factor (TF) in the presence of 4 mM phospholipids, by means of the
Calibrated Automated Thrombogram.
doi:10.1371/journal.pone.0066977.t002
Thrombin Generation and Myocardial Infarction
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Although there appears to be an effect of common cardiovas-
cular risk factors including BMI, cholesterol and triglycerides on
the plasma phenotype, such effects were modest at best in the
present analysis. The effect of BMI was recently found to be due to
total body fat in an analysis of the Hoorn study [11] and probably
mediated by inflammation. The effect of cholesterol and
triglyceride has also been postulated to influence coagulation in
earlier studies [12]. Obviously, there is also the possibility of
unrecognized confounding.
The use of medication that might affect thrombin generation,
including aspirin and statins did not affect any of the thrombin
generation variables. For aspirin an effect in platelet poor plasma
is not to be expected, although one recent report indicates a trend
for accelerated thrombin formation in long-term aspirin users [13].
The use of statins might have attenuated thrombin generation in
platelet poor plasma, as reported in several studies [14–16]. The
fact that we did not observe any effects may have been due to the
relatively low percentage of statin users in the present study.
The present data provide circumstantial support for a causal
association between hypercoagulability and arterial vascular
disease, as can be postulated on the basis of extensive experimental
data [1]. Increased thrombin production may add to the risk of
thrombosis in conditions, such as atherosclerosis, when the
anticoagulant reserve may be limited and erosion or rupture of
the atherosclerotic plaque cannot be properly compensated,
resulting in atherothrombosis. It is uncertain which mechanisms
link cardiovascular risk factors to thrombin generation, but
inflammation driven tissue factor production within the vascula-
ture may be a common mechanism. Inflammatory activity can
trigger hypercoagulability in various ways, involving cellular and
plasma compartments. In our analysis we only observe effects in
platelet poor plasma, which however is the product of interactions
with vessel wall and other cellular mediated reactions. It is
attractive to consider the plasma coagulation proteome, studied in
the in vitro thrombin generation assay, as a product of the
bidirectional interplay between clotting, vessel wall and inflam-
matory systems. This may explain occasional ‘‘paradoxical’’
outcomes as prolonged lag time or reduced ETP and peak height
[3] in patients in the acute phase of coronary artery disease, where
Table 4. Distribution of thrombin generation parameters and odds ratios for myocardial infarction.
Adjusted
Patients Controls OR (95% CI) OR* (95% CI)
(n =171) (n=185)
@ 1 pM TF
Lag Time
,7.66 146 (85) 167 (90) 1 1
.7.66 25 (15) 18 (10) 1.6 (0.8–3.0) 1.225 (0.6–2.4)
nETP
,211 133 (78) 167 (90) 1 1
.211 38 (22) 18 (10) 2.7 (1.4–4.9 2.4 (1.3–4.5)
nPeak Height
,336 135 (79) 167 (90) 1 1
.336 36 (21) 18 (10) 2.5 (1.3–4.6) 2.6 (1.3–5.0)
Reduced ETP
, 214 145 (85) 167 (90) 1 1
. 214 26 (15) 18 (10) 1.7 (0.9–3.2) 1.7 (0.8–3.3)
@ 2 pM TF
Lag Time
,4.33 153 (89) 167 (90) 1 1
.4.33 18 (11) 18 (10) 2.1 (0.9–4.6) 2.0 (0.9–4.7)
nETP
,248 140 (82) 167 (90) 1
.248 31 (18) 18 (10) 2.1 (1.1–3.8) 2.1 (1.1–4.0)
nPeak Height
,311 141 (82) 167 (90) 1 1
.311 30 (18) 18 (10) 2.0 (1.1–3.7) 2.0 (1.0–4.1)
Reduced ETP
, 220 136 (80) 162 (88) 1 1
. 220 27 (16) 17 (9) 1.9 (1.0–3.6) 1.8 (0.8–3.7)
Ref, reference category; 95% CI, 95% confidence interval. OR are relative to the reference category. OR* adjusted for stratifying factors (hypertension, BMI,
hyperlipidemia, diabetes mellitus, history of smoking and gender) at the time of blood sampling. Thrombin generation was assessed at a trigger of 1 or 2 pM TF in the
presence of 4 mM phospholipids. Thrombin generation parameters included lag time, normalized ETP (nETP), normalized peak height (nPeak Height) and the reduction
on ETP upon addition of thrombomodulin (reduced ETP).
doi:10.1371/journal.pone.0066977.t004
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counteracting forces (including TFPI) may delay but not impair
thrombin generation in plasma.
Several comments regarding the study design and interpretation
of outcomes should be made. First, MI was defined according to
the WHO-MONICA criteria from 1994, which may have resulted
to greater heterogeneity in the case selection than would have
occurred according to current criteria. Second, inherent to the
study design, where blood sampling in the cases took place three to
nine months after the MI no firm conclusions can be drawn on
causality. The possibility of reverse causation should indeed be
considered. Besides, the diagnostic value of in vitro thrombin
generation analysis remains to be established. Given the substan-
tial overlap in thrombin generation values between cases and
controls, it is unlikely that thrombin generation analysis will
provide a diagnostic or prognostic tool for coronary disease. The
main advantage of this and similar studies is to obtain better
insight in the contribution of plasmatic hypercoagulability to
cardiovascular disease, which may ultimately help to identify
patients at high risk of fibrin clot formation.
As expected in this case-control design, the case group shows
more unfavorable risk factors for cardiovascular disease than the
control group, although blood pressure was lower in the cases.
This probably reflects blood pressure lowering therapy as
secondary prevention after the MI.
A limitation of the study is the significant time of storage of
plasma samples until assay, a potential problem in all studies
relying on stored plasma material. However, any measurement
error incurred by long-term storage would lead to underestimation
of the case-control differences. While limited literature [17,18]
suggests there may be some loss in factor VII and factor VIII
activities in stored samples over time there is no good reason to
expect that, other than a systemic effect on all plasma determi-
nations, this would alter the differences between cases and
controls. Nevertheless, the potential of storage associated effects
on the laboratory data cannot be excluded. A confounding effect
of contact activation at these rather low TF triggers cannot be fully
excluded, however, one would have expected a shortening of lag
time in case of a significant contribution of contact driven
thrombin generation. These test conditions were chosen in order
to make the test sufficiently sensitive to the expected, modest
differences in thrombin generation that might have escaped
detection at the most common 5 pM TF concentration. The
downside may be that the TG analysis becomes more sensitive to
artificial contact activation [7,19,20]. In spite of a certain
uncertainty about contact activation interference, there is no good
reason to suspect that a random effect of contact activation would
contribute to a systematic difference between values in cases and
controls. Therefore, we conclude that the observed differences are
patient related in cause and not due to pre-analytical artifacts.
In conclusion, we report sustained increases in thrombin
generation three to nine months after a MI. Whether this
hypercoagulable state indicates specific patients at risk of arterial
thrombosis, due to increased plasma based clotting activity, posing
a risk factor for recurrent cardiovascular disease, should be the
topic of further research.
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